GCM
BBNX icon

Ghisallo Capital Management’s Beta Bionics BBNX Stock Holding History

Ghisallo Capital Management’s Portfolio BBNX Stock Details BBNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-25,000
Closed -$497K – 259
2025
Q3 		$497K Sell
25,000
-25,000
-50% -$439K 0.02% 207
2025
Q2 		$728K Hold
50,000
– – 0.02% 173
2025
Q1 		$612K Buy
+50,000
New +$932K 0.05% 99

Other funds holding BBNX

EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return

Ghisallo Capital Management's BBNX Position: Q4 2025 in Review

Ghisallo Capital Management sold out of Beta Bionics (BBNX) in Q4 2025, closing a stake of 25,000 shares — an estimated $497K sold.

Ghisallo Capital Management first reported a position in BBNX in Q1 2025 and held it in 3 quarters. The position peaked at $728K in Q2 2025. 158 funds tracked by Wall St. Rank hold BBNX as of Q4 2025.

  • Ghisallo Capital Management reported no remaining Beta Bionics position as of Q4 2025 after selling out during the quarter.
  • Ghisallo Capital Management sold 25,000 Beta Bionics shares in Q4 2025, an estimated $497K.
  • Ghisallo Capital Management first reported a position in Beta Bionics in Q1 2025 and held it in 3 quarters.
  • Ghisallo Capital Management's Beta Bionics position peaked at $728K in Q2 2025.
  • 158 funds tracked by Wall St. Rank held Beta Bionics as of Q4 2025.

Based on Ghisallo Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.